Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Study Details
Study Description
Brief Summary
This study evaluates the relationship of biomarker expression and efficacy of bevacizumab plus chemotherapy in patients with unresectable/metastatic colorectal cancer. Before the treatment, the investigators detect the VEGF-A,VEGF-C,VEGF-D,VEGFR-1,VEGFR-2,VEGFR-3 expression in tumor tissue by IHC and detect those protein expression level in plasma by ELISA. After at least 6 weeks treatment, the investigators detect again VEGF-A,VEGF-C,VEGF-D expression level in plasma by ELISA. The aim of the study is to identify whether those biomarkers could predict Bevacizumab efficacy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Bevacizumab plus chemotherapy（XELOX or FOLFOX） Bevacizumab plus XELOX (Bevacizumab 7.5mg/kg d1;Xeloda 2g/m2 d1-14 divided into two times;Oxaliplatin 130mg/m2 d1;repeated in 21 days) Bevacizumab plus FOLFOX (Oxaliplatin 85mg/ m2 ivgtt d1;CF 200mg/ m2 ivgtt d1;Bevacizumab 5mg/kg ivgtt d1 5-FU 400mg /m2 ivgtt d1;5-FU 2400mg/m2 CIV 48h;repeated in 14 days) |
Drug: Oxaliplatin
Other Names:
Drug: Xeloda
Other Names:
Drug: Calcium folinate (CF)
Other Names:
Drug: 5-FU
Drug: Bevacizumab
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Overall response rate [36 months]
During the chemotherapy,all the patients demonstrate CT scan or MR to evaluate tumor response to therapy every two cycles.According to RECIST 1.1,tumor response was recorded.
Secondary Outcome Measures
- progression free survival [36 months]
The start time point was defined as when patients receive the first cycle chemotherapy.The end time point was defined as When tumor response to therapy was evaluated as PD according to RECIST 1.1 or patients die for any reason.
- overall survival [36 months]
From the time patients receive the first cycle chemotherapy to the time they die for any reason.
- Number of Participants with Adverse Events [36 months]
Every cycle we demonstrate routine blood test,routine urine test,routine stool test,blood biochemical test.We recommend patients take blood pressure at least twice a week during the therapy.If needed,patients also need have electrocardiogram test and echocardiography.We will evaluate the toxicity according to CTCAE4.0
Eligibility Criteria
Criteria
Inclusion Criteria:
-
More than 18-years old,male or female
-
Pathologically approved as unresectable/metastatic colorectal cancer
-
KPS > 70% or ECOG 0-2
-
HGB > 80 g/L, NEUT ≥ 1.5x109 /L, PLT ≥ 80x109 /L; CR < 1.5 x Upper normality，
-
TB < 1.5 X Upper normality，AST or ALT < 2.5 x Upper normality.
-
Signed consent
Exclusion Criteria:
-
Other malignancies simultaneously except in situ cervix or nonmelanoma skin cancer
-
Pregnancy or in lactation
-
HGB < 80 g/L, NEUT < 1.5x109 /L, PLT < 80x109 /L; CR ≥ 1.5 x Upper normality， TB ≥ 2.5 X Upper normality，AST or ALT ≥2.5 x Upper normality，AKP ≥ 2.5 X Upper normality
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cancer Institute&Hospital Chinese Academy of Medical Sciences | Beijing | China |
Sponsors and Collaborators
- Chinese Academy of Medical Sciences
Investigators
- Principal Investigator: Yihebali Chi, Doctor, Chinese Academy of Medical Sciences
- Study Director: Jinwan WANG, Chinese Academy of Medical Sciences
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- WY0524